Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

European Union
European Commission v Republic of Poland (C-185/10)
Judgment
The action
Findings of the Court
42

European Commission v Republic of Poland (C-185/10)

law://eu/cjeu/2010/c-185-10/para_42@2026-11-13

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

Key facts

Court: Court of Justice · Third Chamber
Case: C-185/10 · ECLI:EU:C:2012:181
Decided: 29 Mar 2012
Procedure: Infringement action
Applicant: European Commission
Defendant: Republic of Poland
Rapporteur: D. Šváby
Advocate General: N. Jääskinen
Bench: 5 judges
K. Lenaerts, E. Juhász, G. Arestis, T. von Danwitz, D. Šváby
Language: Polish
Official: CURIA · EUR-Lex 62010CJ0185

Topics

Pharmaceutical and cosmetic products

History · 1 version

29 Mar 2012Reading

Judgment of 29 Mar 2012

42Those provisions thus allow the importation and the placing on the national market, without a marketing authorisation, of medicinal products which are not necessary to meet special medical needs.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Connections

Cited by 8: Abcur AB v Apoteket Farmaci AB and Apoteket AB (C-544/13, C-545/13); Pharma Expressz Szolgáltató és Kereskedelmi Kft v Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet (C-178/20)2 provisions; Staat der Nederlanden v Warner-Lambert Company LLC (C-423/17); Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others (C-29/17); F. Hoffmann-La Roche Ltd and Others v Autorità Garante della Concorrenza e del Mercato (C-179/16); Miguel M. and Others (C-627/13, C-2/14); Laboratoires CTRS v European Commission (T-301/12)3 provisions; Novartis Pharma GmbH v Apozyt GmbH (C-535/11)2 provisions
Cites 5: Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; Staat der Nederlanden v Antroposana, Patiëntenvereniging voor Antroposofische Gezondheidszorg and Others (C-84/06); Ludwigs - Apotheke München Internationale Apotheke v Juers Pharma Import-Export GmbH (C-143/06); A. Menarini Industrie Farmaceutiche Riunite Srl and Others v Ministero della Salute and Agenzia Italiana del Farmaco (AIFA), Sanofi Aventis SpA v Agenzia Italiana del Farmaco (AIFA), IFB Stroder Srl v Agenzia Italiana del Farmaco (AIFA), Schering Plough SpA v Agenzia Italiana del Farmaco (AIFA), Bayer SpA v Agenzia Italiana del Farmaco (AIFA) and Ministero della Salute, Simesa SpA v Ministero della Salute and Agenzia Italiana del Farmaco (AIFA), Abbott SpA v Ministero della Salute and Agenzia Italiana del Farmaco (AIFA), Baxter SpA v Agenzia Italiana del Farmaco (AIFA) and SALF SpA v Agenzia Italiana del Farmaco (AIFA) and Ministero della Salute (C-352/07); Erotic Center BVBA v Belgische Staat (C-3/09)